Jazz Pharmaceuticals PLC $ 119.65 -1.48 (-1.22%)
Volume:
526,611
Avg Vol (1m):
520,397
Market Cap $:
6.77 Bil
Enterprise Value $:
7.66 Bil
P/E (TTM):
10.80
P/B:
2.30
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
| Peter Lynch Value | ||
|
Price: $119.65 | ||
Manual of Stocks™ Web
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.5 | ||
| Equity-to-Asset | 0.54 | ||
| Debt-to-Equity | 0.59 | ||
| Debt-to-EBITDA | 1.77 | ||
| Interest Coverage | 10.55 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 2.89 | ||
| Beneish M-Score | -2.45 | ||
| WACC vs ROIC | |||
Profitability | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 38.73 | ||
| Net Margin % | 32.99 | ||
| ROE % | 22.82 | ||
| ROA % | 12.23 | ||
| ROC (Joel Greenblatt) % | 220.4 | ||
| 3-Year Revenue Growth Rate | 13.7 | ||
| 3-Year EBITDA Growth Rate | 11.6 | ||
| 3-Year EPS without NRI Growth Rate | 11.8 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 10.8 | ||
| Forward PE Ratio | 7.07 | ||
| PE Ratio without NRI | 10.8 | ||
| Price-to-Owner-Earnings | 15.07 | ||
| PB Ratio | 2.3 | ||
| PS Ratio | 3.57 | ||
| Price-to-Free-Cash-Flow | 10.6 | ||
| Price-to-Operating-Cash-Flow | 9.02 | ||
| EV-to-EBIT | 9.94 | ||
| EV-to-EBITDA | 7.68 | ||
| EV-to-Revenue | 3.85 | ||
| PEG Ratio | 0.74 | ||
| Shiller PE Ratio | 24.67 | ||
| Current Ratio | 3.71 | ||
| Quick Ratio | 3.52 | ||
| Days Inventory | 174.2 | ||
| Days Sales Outstanding | 57.14 | ||
| Days Payable | 263.04 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 0.75 | ||
| Price-to-Median-PS-Value | 0.6 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.8 | ||
| Earnings Yield (Greenblatt) % | 10.06 | ||
| Forward Rate of Return (Yacktman) % | 20.3 |